Food and Drug Administration (2003). Final report on pharmaceutical cGMPs for the 21st century—A risk-based approach. http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm
(Accessed April 6, 2005).
L. X. Yu, A. Raw, R. Lionberger, R. Rajagopalan, L. Lee, F. Holcombe, R. Patel, F. Fang, V. Sayeed, P. Schwartz, R. Adams, and G. Buehler. U.S. FDA question-based review for generic drugs: A new pharmaceutical quality assessment system. J. Generic Med
:239–248 (2007).CrossRefGoogle Scholar
Food and Drug Administration CDER. Guidance for industry, Q8 pharmaceutical development (May 2006).
M. Nasr. Risk-based CMC review paradigm. Advisory committee for pharmaceutical science meeting, July 20–21, 2004.
Food and Drug Administration CDER. Guidance for industry: Immediate release solid oral dosage forms scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation (November 1995).
Food and Drug Administration CDER. Guidance for industry: Modified release solid oral dosage forms scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation (September 1997).
Food and Drug Administration CDER. Guidance for industry: Nonsterile semisolid dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation (May 1997).
Food and Drug Administration CDER. Guidance for industry: Changes to an approved NDA or ANDA (April 2004).
J. Woodcock. The concept of pharmaceutical quality. Am. Pharm. Rev. November–December, 1–3, 2004.
Food and Drug Administration Office of Generic Drugs White Paper on Question-based Review. http://www.fda.gov/cder/OGD/QbR.htm
Food and Drug Administration CDER. Guidance for industry, Q6A specifications for new drug substances and products: Chemical substances (October 1999).
M. Nasr. FDA’s quality initiatives: An update. http://www.gmp-compliance.com/daten/download/FDAs_Quality_Initiative.pdf
(Accessed Nov. 10, 2007).
IBM Business Consulting Services (2005). Transforming industrialization: A new paradigm for pharmaceutical development. http://www-935.ibm.com/services/us/imc/pdf/ge510–3997-transforming-industrialization.pdf
(Accessed November 16, 2006).
H. Zhang, and L. X. Yu. Dissolution testing for solid oral drug products: Theoretical considerations. Am. Pharm. Rev., September, 26–31, 2004.
J. E. Polli, G. S. Rekhi, L. L. Augsburger, and V. P. Shah. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J. Pharm. Sci
:690–700 (1997).PubMedCrossRefGoogle Scholar
R. Takano, K. Sugano, A. Higashida, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita. Oral aborption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res
:1144–1156 (2006).PubMedCrossRefGoogle Scholar
Food and Drug Administration CDER. Guidance for industry, Q3B (R2) impurities in new drug product (July 2006).
Food and Drug Administration CDER. Draft guidance for industry, ANDAs: Impurities in drug products (August 2005).
J. M. Delasko, D. M. Cocchetto, and L. B. Burke. Target product profile: Beginning drug development with the end in mind. Update,
January/February, Issue 1, 2005, http://www.fdli.org
Food and Drug Administration CDER. Draft guidance for industry and review staff: Target product profile—A strategic development tool (March 2007).
Food and Drug Administration Office of Generic Drugs. Model quality overall summary for IR product. http://www.fda.gov/cder/ogd/OGD_Model_QOS_IR_Product.pdf
(Accessed March 31, 2006).
G. E. Amidon, X. He, M. J. Hageman. Burgers medicinal chemistry and drug discovery, vol 2., Ch 18. In D. J. Abraham (eds). Wiley-Interscience, New York, 2004.
L. X. Yu, M. S. Furness, A. Raw, K. P. Woodland Outlaw, N. E. Nashed, E. Ramos, S. P. F. Miller, R. C. Adams, F. Fang, R. M. Patel, F. O. Holcombe Jr., Y. Chiu, and A. S. Hussain. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm. Res
:531–536 (2003).PubMedCrossRefGoogle Scholar
A. S. Raw, M. S. Furness, D. S. Gill, R. C. Adams, F. O. Holcombe Jr., and L. X. Yu. Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs). Adv. Drug Deliv. Rev
:397–414 (2004).PubMedCrossRefGoogle Scholar
S. P. F. Miller, A. S. Raw, and L. X. Yu. FDA perspective on pharmaceutical solid polymorphism. In R. Hilfiker (ed.), Polymorphism—In the Pharmaceutical and Fine Chemical Industry, Wiley-VCH, New York, 2006.
G. E. Amidon. Intrinsic properties of drug substance, excipients, and process selection. FDA OGD regulatory science training series. Manufacturing science and scale-up challenges. May 23, 2005.
D. Sun, L. X. Yu, M. A. Hussain, D. A. Wall, R. L. Smith, and G. L. Amidon. In Vitro testing of drug absorption for drug “developability” assessment: Forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel. 7:75–85 (2004).
L. X. Yu. An integrated absorption model for determining causes of poor oral drug absorption. Pharm. Res
:1883–1887 (1999).PubMedCrossRefGoogle Scholar
L. X. Yu, C. D. Ellison, and A. S. Hussain. Predicting human oral bioavailability using in silico models. In R. Krishna (ed.), Applications of Pharmacokinetics Principles in Drug Development
, Kluwer, New York, 2004.Google Scholar
G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res
:413–420 (1995).PubMedCrossRefGoogle Scholar
Food and Drug Administration CDER. Guidance for industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000, CDER/FDA.
L. X. Yu, G. L. Amidon, J. E. Polli, H. Zhao, M. Mehta, D. P. Conner, V. P. Shah, L. J. Lesko, M.-L. Chen, V. H. L. Lee, and A. S. Hussain. Biopharmaceutics Classification System: The scientific basis for biowaiver extension. Pharm. Res
:921–925 (2002).PubMedCrossRefGoogle Scholar
J. E. Polli, L. X. Yu, J. A. Cook, G. L. Amidon, R. T. Borchardt, B. A. Burnside, P. S. Burton, M. L. Chen, D. P. Conner, P. J. Faustino, A. A. Hawi, A. S. Hussain, H. N. Joshi, G. Kwei, V. H. L. Lee, L. J. Lesko, R. A. Lipper, A. E. Loper, S. G. Nerurkar, J. W. Polli, D. R. Srdeker, R. Taneja, R. S. Uppoor, C. S. Vattikonda, I. Wilding, and G. Zhang. Summary workshop report: Biopharmaceutics classification system – implementation challenges and extension opportunities. J. Pharm. Sci
:1375–81 (2004).PubMedCrossRefGoogle Scholar
G. E. Amidon. Physical and mechanical property characterization of powders. In H. G. Brittain (ed.), Physical Characterization of Pharmaceutical Solid. Marcel Dekker, New York 1995, pp. 281–320.
S. Jain. Mechanical properties of powders for compaction and tableting: an overview. PSTT
:20–31 (1999).Google Scholar
H. Dubin. Formulation frustrations. Drug Deliv. Technol. 5(8), 2005 (September).
R. K. Verma, and S. Garg. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing. Int. J. Pharm. Biomed. Ana
:633–644 (2005).CrossRefGoogle Scholar
K. C. Waterman, and R. C. Adami. Accelerated aging: Prediction of chemical stability of pharmaceuticals. Int. J. Pharm
:101–125 (2005).PubMedCrossRefGoogle Scholar
R. Kandarapu, V. Grover, H. P. S. Chawla, and S. Garg. S. T. P. Pharma Sci
:449–457 (2001).Google Scholar
A. T. M. Serajuddin, A. B. Thakur, R. N. Ghoshal, M. G. Fakes, S. A. Ranadive, K. R. Morris, and S. A. Varia. Selection of solid dosage form composition through drug-excipient compatibility testing. J. Pharm. Sci
:696–704 (1999).PubMedCrossRefGoogle Scholar
M. Gibson. Product optimization. In M. Gibson (ed.), Pharmaceutical Preformulation and Formulation. Taylor & Francis, New York, 2001, pp. 295–330.
M. D. Tousey. The granulation process 101, basic technologies for tablet making. Pharm. Tech. Tableting and Granulation. 2002.
D. P. Petrides, A. Koulouris, and P. T. Lagonikos. The Role of process simulation in pharmaceutical process development and product commercialization. Pharm. Eng
:1–8 (2002).Google Scholar
W. P. Ganzer, J. A. Materna, M. B. Mitchell, and L. K. Wall. Current thoughts on critical process parameters (CPP’s) and API Syntheses. Pharm Tech., July 2, 2005.
F. A. Menard. Quality by design in generic drug development. Presentation to FDA Office of Generic Drugs. September 25, 2006.
M. Glodek, S. Liebowitz, R. mcCarthy, G. McNally, C. Oksanen, T. Schultz, M. Sundararajan, R. Vorkapich, K. Vukovinsky, C. Watts, and G. Millili. Process robustness—A PQRI white paper. Pharm. Eng
:1–11 (2006).Google Scholar
Rath and Strong. Design for six-sigma pocket guide. Rath and Strong Management Consutants/AON Management Consulting, Lexington, MA (2002).
C. Chen. Implementing quality by design: ONDQA initiatives. Advisory Committee for Pharmaceutical Science October 5, 2006. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006–4241s1-index.htm
(Accessed December 1, 2006).
National Institute for Pharmaceutical Technology and Education. Strategic roadmap for research and education. http://www.nipte.org
Food and Drug Administration CDER. Guidance for industry, PAT—A framework for innovative pharmaceutical development, manufacturing, and quality assurance. September 2006.
L. X. Yu, R. A. Lionberger, A. S. Raw, R. D’Costa, H. Wu, and A. S. Hussain. Application of process analytical technology to crystallization process. Adv. Drug Del. Rev
:349–369 (2004).CrossRefGoogle Scholar
C. Watts, and J. E. Clark. PAT: Driving the future of pharmaceutical quality. J. Pro. Ana. Tech
(6):6–9 (2006).Google Scholar